Axa
VIRX

Axa’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Axa’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-2,081
Closed -$3.12M – 1495
2014
Q3 		$3.12M Sell
2,081
-734
-26% -$1.06M 0.01% 640
2014
Q2 		$3.85M Sell
2,815
-113
-4% -$131K 0.02% 624
2014
Q1 		$4.07M Buy
2,928
+1,253
+75% +$1.46M 0.02% 576
2013
Q4 		$1.67M Buy
+1,675
New +$1.73M 0.01% 813

Other funds holding VIRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Axa's VIRX Position: Q4 2014 in Review

Axa sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2014, closing a stake of 2,081 shares — an estimated $3.12M sold.

Axa first reported a position in VIRX in Q4 2013 and held it in 4 quarters. The position peaked at $4.07M in Q1 2014. 78 funds tracked by Wall St. Rank hold VIRX as of Q4 2014.

  • Axa reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2014 after selling out during the quarter.
  • Axa sold 2,081 Viracta Therapeutics, Inc. Common Stock shares in Q4 2014, an estimated $3.12M.
  • Axa first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2013 and held it in 4 quarters.
  • Axa's Viracta Therapeutics, Inc. Common Stock position peaked at $4.07M in Q1 2014.
  • 78 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2014.

Based on Axa's 13F filing for Q4 2014, filed 13 Feb 2015.